NICE Technology Appraisals: Formulary Adherence Checklist

NICE technology appraisals (TAs) are published on the fourth Wednesday of each month, except for December when it is published earlier

Produced by Medicines Information, Pharmacy, Sunderland Royal Hospital

Updated 27.9.17

Technology appraisal (TA) Titles are hyperlinks to full guidance		***Availability of medicine for NHS patients with this medical condition, as indicated by NICE***	***Adherence of local formulary to NICE***							
			Yes *(mark 'x' if applicable)*	***N/A*** *(mark 'x' if applicable)*	***Published***	***Date of local decision*** *(DD/MM/YY)*	***Final Date to Implement***	***Time to implement*** *as requested by NICE (days)*	***Time taken to implement in Sunderland*** *(days)*	***Notes***
2017-18										
TA476	Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer	**Paclitaxel as albumin-bound nanoparticles (nab‑paclitaxel)** with **gemcitabine** is **recommended as an option** for untreated metastatic adenocarcinoma of the pancreas in adults, only if other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy	X		06/09/2017	27/09/17	05/12/2017	90	21	
TA475	Dimethyl fumarate for treating moderate to severe plaque psoriasis	**Dimethyl fumarate** is **recommended as an option** for treating plaque psoriasis in adults, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and has not responded to other systemic therapies, including, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.	X		06/09/2017	27/09/17	05/12/2017	90	21	
TA474	Sorafenib for treating advanced hepatocellular carcinoma	**Sorafenib** is recommended as an **option** for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment.	X		06/09/2017	27/09/17	05/12/2017	90	21	
TA473	Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	**Cetuximab in combination with platinum-based chemotherapy** is **recommended as an option** for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only if the cancer started in the oral cavity	X		30/08/2017	27/09/17	28/11/2017	90	28	

TA472	Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab	**Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is recommended** for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed.	X		30/08/2017	27/09/17	28/11/2017	90	28	CDF
TA471	Eluxadoline for treating irritable bowel syndrome with diarrhoea	**Eluxadoline is recommended** as an **option** for treating irritable bowel syndrome with diarrhoea in adults, only if the condition has not responded to other pharmacological treatments (for example, antimotility agents, antispasmodics, tricyclic antidepressants) or pharmacological treatments are contraindicated or not tolerated, and it is started in secondary care.	X		30/08/2017	27/09/17	28/11/2017	90	28	
TA470	Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia because no evidence submission was received from Novartis Pharmaceuticals UK.		X	23/08/2017	27/09/17	21/11/2017	90	N/A	Terminated appraisal
TA469	Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received from Gilead Sciences.		X	23/08/2017	27/09/17	21/11/2017	90	N/A	Terminated appraisal
TA468	Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence submission was received from Swedish Orphan Biovitrum Ltd		X	23/08/2017	27/09/17	21/11/2017	90	N/A	Terminated appraisal
TA467	Holoclar for treating limbal stem cell deficiency after eye burns	**Holoclar** (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is **recommended** as an **option** in people with moderate to severe limbal stem cell deficiency after eye burns, only if it is only used to treat 1 eye and people have already had a conjunctival limbal autograft or there is not enough tissue for a conjunctival limbal autograft or it is contraindicated.	X		16/08/2017	27/09/17	14/11/2017	90	42	

TA466	Baricitinib for moderate to severe rheumatoid arthritis	**Baricitinib**, with **methotrexate**, is recommended as an **option** for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if disease is severe (a disease activity score [DAS28] of more than 5.1). **Baricitinib**, with **methotrexate**, is recommended as an **option** for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if disease is severe (a DAS28 of more than 5.1) andthey cannot have rituximab. **Baricitinib** can be used as **monotherapy** for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the above criteria are met.	X		09/08/2017	27/09/17	07/11/2017	90	49	
TA465	Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma	**Olaratumab**, in combination with **doxorubicin**, is **recommended** for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only if they have not had any previous systemic chemotherapy for advanced soft tissue sarcoma, they cannot have curative treatment with surgery or their disease does not respond to radiotherapy.	X		09/08/2017	27/09/17	07/11/2017	90	49	
TA464	Bisphosphonates for treating osteoporosis	Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) and intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and the 10‑year probability of osteoporotic fragility fracture is at least 1% (for oral) or at least 10% (for IV). For IV, if the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated.	X	X	09/08/2017	27/09/17	07/11/2017	90	49	

TA463	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	**Nivolumab** is **recommended** as an **option** for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, **when the company provides nivolumab with the discount agreed in the patient access scheme**.	X		26/07/2017	27/09/17	24/10/2017	90	53	
TA462	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	**Nivolumab** is recommended**, as an** option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, **when the company provides nivolumab with the discount agreed in the patient access scheme.**	X		26/07/2017	27/09/17	24/10/2017	90	53	
TA461	Roflumilast for treating chronic obstructive pulmonary disease	**Roflumilast**, as an add-on to bronchodilator therapy, is **recommended** as an **option** for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid. Treatment with roflumilast should be started by a specialist in respiratory medicine.	X		26/07/2017	27/09/17	24/10/2017	90	53	
TA460	Adalimumab and dexamethasone for treating non-infectious uveitis	**Adalimumab** is **recommende**d as an **option** for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, only if there is active disease (that is, current inflammation in the eye) and inadequate response or intolerance to immunosuppressants and systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) and worsening vision with a high risk of blindness (for example, risk of blindness that is similar to that seen in people with macular oedema).	X		26/07/2017	27/09/17	24/10/2017	90	53	

TA459	Collagenase clostridium histolyticum for treating Dupuytren's contracture	People who meet the inclusion criteria for the ongoing clinical trial (HTA-15/102/04), comparing collagenase clostridium histolyticum (CCH) with limited fasciectomy, are encouraged to participate in the study. For people not taking part in the ongoing clinical trial, CCH is recommended as an option for treating Dupuytren's contracture with a palpable cord in adults only if all of the following apply: There is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture) plus up to 2 affected joints. Percutaneous needle fasciotomy (PNF) is not considered appropriate, but limited fasciectomy is considered appropriate by the treating hand surgeon. The choice of treatment (CCH or limited fasciectomy) is made on an individual basis after discussion between the responsible hand surgeon and the patient about the risks and benefits of the treatments available. One injection is given per treatment session by a hand surgeon in an outpatient setting.	X		26/07/2017	27/09/17	24/10/2017	90	53	
TA458	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane	**Trastuzumab emtansine** is **recommended** as an **option** for treating human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy	X		19/07/2017	27/09/17		90	60	
TA457	Carfilzomib for previously treated multiple myeloma	**Carfilzomib** in combination with dexamethasone is **recommended** as an **option** for treating multiple myeloma in adults, only if they have had only 1 previous therapy, which did not include bortezomib	X		19/07/2017	27/09/17	17/10/2017	90	60	
TA456	Ustekinumab for moderately to severely active Crohn's disease after previous treatment	**Ustekinumab** is **recommended** as an **option** for treating moderately to severely active Crohn's disease, that is, for adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha inhibitor or have medical contraindications to such therapies. The choice of treatment between ustekinumab or another biological therapy should be made on an individual basis.	X		19/07/2017	27/09/17	17/10/2017	90	60	

TA455	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	**All** are **recommended** as an **option**, only if the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.	X		19/07/2017	27/09/17	17/10/2017	90	60	
TA454	Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag.		X	05/07/2017	27/09/17	03/10/2017	90	N/A	Terminated appraisal
TA453	Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no evidence submission was received from Janssen-Cilag		X	05/07/2017	27/09/17	03/10/2017	90	N/A	Terminated appraisal
TA452	Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag.		X	05/07/2017	27/09/17	03/10/2017	90	N/A	Terminated appraisal
TA451	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	**Ponatinib** is **recommended** as an **option** for treating chronic-, accelerated- or blast-phase chronic myeloid leukaemia in adults when the disease is resistant to dasatinib or nilotinib or they cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or the T315I gene mutation is present. **Ponatinib** is recommended as an **option** for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults when the disease is resistant to dasatinib or they cannot tolerate dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate or the T315I gene mutation is present.	X		28/06/2017	26/07/17	26/09/2017	90	28	
TA450	Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	**Blinatumomab** is **recommended** as an **option** for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults.	X		28/06/2017	26/07/17	26/09/2017	90	28	

TA449	Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	**Everolimus** and **sunitinib** are **recommended** as **options** for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. **Everolimus** is **recommended** as an **option** for treating well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease.	X		28/06/2017	26/07/17	26/09/2017	90	28	Already in the Formulary
TA448	Etelcalcetide for treating secondary hyperparathyroidism	**Etelcalcetide** is recommended as an **option** for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, only if treatment with a calcimimetic is indicated but cinacalcet is not suitable.	X		28/06/2017		26/09/2017	90	90	
TA447	Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	**Pembrolizumab** is **recommended** for use within the CDF as an **option** for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults, only if their tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations and if pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression.	X		28/06/2017		26/09/2017	90	90	CDF
TA446	Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	**Brentuximab vedotin** is **recommended** as anfor treating CD30‑positive Hodgkin lymphoma in adults, only if they have relapsed or refractory disease after autologous stem cell transplant	X		28/06/2017		26/09/2017	90	90	NHSE/CDF
TA445	Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	**Certolizumab pegol** or **secukinumab** alone, or in combination with methotrexate, is **recommended** as an **option f**or treating active psoriatic arthritis in adults only if the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.	X		24/05/2017		22/08/2017	90	90	Already in the Formulary
TA444	Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from Boehringer Ingelheim. We will review this decision if the company decides to make a submission.		X	24/05/2017		22/08/2017	90	N/A	Terminated appraisal

TA443	Obeticholic acid for treating primary biliary cholangitis	**Obeticholic acid** is **recommended as an option** for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid.	X		26/04/2017	31/05/2017	25/07/2017	90	35	
TA442	Ixekizumab for treating moderate to severe plaque psoriasis	**Ixekizumab** is **recommended as an option** for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10; the disease has not responded to standard systemic therapies, or these treatments are contraindicated or the person cannot tolerate them.		X	26/04/2017	31/05/2017	25/07/2017	90	N/A	Service supplied by Durham
TA441	Daclizumab for treating relapsing–remitting multiple sclerosis	**Daclizumab** is **recommended as an option** for treating multiple sclerosis in adults, only if: the person has active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and alemtuzumab is contraindicated or otherwise unsuitable.	X		26/04/2017	31/05/2017	25/07/2017	90	35	
TA440	Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	**Pegylated liposomal irinotecan**, in combination with **5‑fluorouracil and leucovorin**, is **not recommended** for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.		X	26/04/2017		25/07/2017	90	N/A	Not recommended
TA439	Cetuximab and panitumumab for previously untreated metastatic colorectal cancer	**Cetuximab** is **recommended as an option** for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with: 5‑fluorouracil, folinic acid and oxaliplatin (FOLFOX) or 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI).**Panitumumab** is **recommended as an option** for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with: FOLFOX or FOLFIRI.	X		29/03/2017	31/05/2017	27/06/2017	90	63	
TA438	Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)	NICE is unable to make a recommendation because no evidence submission was received from Roche. We will review this decision if the company decides to make a submission.		X	29/03/2017		27/06/2017	90	N/A	Terminated appraisal

TA437	Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	NICE is unable to make a recommendation because no evidence submission was received from Roche. NICE will review this decision if the company decides to make a submission.		X	29/03/2017		27/06/2017	90	N/A	Terminated appraisal
TA436	Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)	NICE is unable to make a recommendation because no evidence submission was received from Roche. NICE will review this decision if the company decides to make a submission.		X	29/03/2017		27/06/2017	90	N/A	Terminated appraisal
TA435	Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)	NICE is unable to make a recommendation because no evidence submission was received from Gilead. NICE will review this decision if the company decides to make a submission.		X	29/03/2017		27/06/2017	90	N/A	Terminated appraisal
TA434	Elotuzumab for previously treated multiple myeloma (terminated appraisal)	NICE is unable to make a recommendation because no evidence submission was received from Bristol-Myers-Squibb. NICE will review this decision if the company decides to make a submission.		X	29/03/2017		27/06/2017	90	N/A	Terminated appraisal
43			15	0		15				
			% "Yes"	**% "N/A"**					**Average implement time** (days)	
	Adherence statistics for 2017-18		100%	0%		100%			**44**	